Your browser doesn't support javascript.
loading
Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer.
Jacobs, Samuel A; Robidoux, André; Abraham, Jame; Pérez-Garcia, José Manuel; La Verde, Nicla; Orcutt, James M; Cazzaniga, Marina E; Piette, Fanny; Antolín, Silvia; Aguirre, Elena; Cortes, Javier; Llombart-Cussac, Antonio; Di Cosimo, Serena; Kim, Rim S; Feng, Huichen; Lipchik, Corey; Lucas, Peter C; Srinivasan, Ashok; Wang, Ying; Song, Nan; Gavin, Patrick G; Balousek, April D; Paik, Soonmyung; Allegra, Carmen J; Wolmark, Norman; Pogue-Geile, Katherine L.
Afiliación
  • Jacobs SA; NSABP Foundation, Inc., Nova Tower 2, Two Allegheny Center - Ste 1200, Pittsburgh, PA, 15212, USA. samuel.jacobs@nsabp.org.
  • Robidoux A; NSABP Foundation, Inc., Nova Tower 2, Two Allegheny Center - Ste 1200, Pittsburgh, PA, 15212, USA.
  • Abraham J; Centre hospitalier de l'université de Montréal, Montréal, QC, Canada.
  • Pérez-Garcia JM; NSABP Foundation, Inc., Nova Tower 2, Two Allegheny Center - Ste 1200, Pittsburgh, PA, 15212, USA.
  • La Verde N; Cleveland Clinic, Cleveland, OH, USA.
  • Orcutt JM; QuironSalud Group, IOB Institute of Oncology, Barcelona, Madrid, Spain.
  • Cazzaniga ME; Medica Scientia Innovation Research (MedSIR), Barcelona, Spain.
  • Piette F; Present address: ASST Fatebenefratelli Sacco - PO Luigi Sacco, Milan, Italy.
  • Antolín S; ASST Fatebenefratelli Sacco - PO Fatebenefratelli, Milan, Italy.
  • Aguirre E; NSABP Foundation, Inc., Nova Tower 2, Two Allegheny Center - Ste 1200, Pittsburgh, PA, 15212, USA.
  • Cortes J; Roper St. Francis Healthcare, Charleston, SC, USA.
  • Llombart-Cussac A; Medica Scientia Innovation Research (MedSIR), Barcelona, Spain.
  • Di Cosimo S; Azienda Ospedaliera San Gerardo, Monza, Italy.
  • Kim RS; International Drug Development Institute (IDDI), Louvain-la-Neuve, Belgium.
  • Feng H; Hospital Universitario, Coruña, Spain.
  • Lipchik C; Medica Scientia Innovation Research (MedSIR), Barcelona, Spain.
  • Lucas PC; QuironSalud Group, IOB Institute of Oncology, Barcelona, Madrid, Spain.
  • Srinivasan A; Medica Scientia Innovation Research (MedSIR), Barcelona, Spain.
  • Wang Y; Medica Scientia Innovation Research (MedSIR), Barcelona, Spain.
  • Song N; Medica Scientia Innovation Research (MedSIR), Barcelona, Spain.
  • Gavin PG; Fondazione IRCCS Istituto Nazionale di Tumori, Milan, Italy.
  • Balousek AD; NSABP Foundation, Inc., Nova Tower 2, Two Allegheny Center - Ste 1200, Pittsburgh, PA, 15212, USA.
  • Paik S; NSABP Foundation, Inc., Nova Tower 2, Two Allegheny Center - Ste 1200, Pittsburgh, PA, 15212, USA.
  • Allegra CJ; NSABP Foundation, Inc., Nova Tower 2, Two Allegheny Center - Ste 1200, Pittsburgh, PA, 15212, USA.
  • Wolmark N; NSABP Foundation, Inc., Nova Tower 2, Two Allegheny Center - Ste 1200, Pittsburgh, PA, 15212, USA.
  • Pogue-Geile KL; Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Breast Cancer Res ; 22(1): 9, 2020 Jan 22.
Article en En | MEDLINE | ID: mdl-31969184
ABSTRACT
After the publication of this work [1] the authors have reported that in Table 3 The letter "T" in columns 5 and 7 should not be there.
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Breast Cancer Res Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Breast Cancer Res Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos